NCT06984432View on ClinicalTrials.gov

"Evaluation of a Non-cross-linked Hyaluronic Acid Medical Device (Electri and XELA REDERM) for Improving Facial Skin Appearance"

NACompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions
Appearance of Facial WrinklesAestheticHydrationFacial Skin Wrinkles
Interventions
DEVICE

XELA REDERM (non-cross-linked hyaluronic acid 1.1%, 1.8%, or 2.2%)

Injectable implant containing 1.1%, 1.8%, or 2.2% non-cross-linked hyaluronic acid with succinic acid, sodium succinate, sodium chloride, and water for injection. Intended for redermalization to improve skin quality through biorevitalization.

DEVICE

Electri (non-cross-linked hyaluronic acid 0.55%)

Injectable implant containing 0.55% non-cross-linked hyaluronic acid with succinic acid, sodium succinate, sodium chloride, and water for injection. Intended for redermalization aimed at improving skin hydration, elasticity, and appearance.

Trial Locations (4)

40-611

Provita Sp. z o.o., Katowice

30-074

Ośrodek medyczny OSTEOMED s.c., Krakow

00-342

Prime Clinic Sp. z o.o., Warsaw

03151

Institute Hyalual LLC, Kyiv

All Listed Sponsors
lead

Institute Hyalual GmbH

INDUSTRY

NCT06984432 - "Evaluation of a Non-cross-linked Hyaluronic Acid Medical Device (Electri and XELA REDERM) for Improving Facial Skin Appearance" | Biotech Hunter | Biotech Hunter